Ergoteles’s Immunome IMNM Stock Holding History

Ergoteles’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,006	Closed	-$173K	–	1427
2021 Q2	$173K	Buy	+10,006	New	+$221K	﹤0.01%	1321

Other funds holding IMNM

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

PCM

Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Ridgewood Investments Springfield, New Jersey $244M AUM

Ergoteles's IMNM Position: Q3 2021 in Review

Ergoteles sold out of Immunome (IMNM) in Q3 2021, closing a stake of 10,006 shares — an estimated $173K sold.

Ergoteles first reported a position in IMNM in Q2 2021 and held it in 1 quarter. The position peaked at $173K in Q2 2021. 35 funds tracked by Wall St. Rank hold IMNM as of Q3 2021.

Ergoteles reported no remaining Immunome position as of Q3 2021 after selling out during the quarter.
Ergoteles sold 10,006 Immunome shares in Q3 2021, an estimated $173K.
Ergoteles first reported a position in Immunome in Q2 2021 and held it in 1 quarter.
Ergoteles's Immunome position peaked at $173K in Q2 2021.
35 funds tracked by Wall St. Rank held Immunome as of Q3 2021.

Based on Ergoteles's 13F filing for Q3 2021, filed 15 Nov 2021.